drugset / Trial / NCT01295710

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

NCT01295710 ↗

Phase 3 Completed 260 enrolled Neovii Biotech
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The study objective is to compare the efficacy and safety of US-ATG-F as a supplement to standard of care prophylaxis versus standard of care prophylaxis alone in moderate to severe chronic GVHD-free survival.

Timeline

Start
2011-10-10
Primary completion
2015-10-15
Completion
2015-10-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator US-ATG-F Protein / enzyme biologic 20 mg/kg Intravenous